ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
value factor · long-only model fund

Foundry RD Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FRDXHYPOTHETICAL MODEL
Since ’99
+1119%
Expense Ratio
0.29%
placeholder
Holdings
106
cap-weighted
Inception
Dec 2019
placeholder
Full Sharpe
0.48
Ann. Return (LS)
12.3%
Ann. Volatility
25.6%
Max Drawdown
-71.7%
Test Sharpe ’19–26
0.49
Test FF5 α (ann.)
22.2%
vs Fama-French 5
Test FF5 α t-stat
2.18
significant (|t| ≥ 2)
Monthly turnover
21%
of the long leg, per rebalance
Cumulative return (LS)
1119%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.68
what this fund holds
Long leg ann. return
20.9%
buyable, long-only
Long-short Sharpe
0.48
requires shorting
Bottom bucket ann. return
8.6%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

106 of 106 · 100.0% of book
TickerCompanySectorMarket capWeight
1MBLY
MOBILEYE GLOBAL INCConsumer Cyclical$7.76B
10.69%
2RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
3.97%
3LCID
LUCID GROUP INCConsumer Cyclical$2.87B
3.95%
4BHVN
BIOHAVEN LTDHealthcare$2.32B
3.20%
5VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
2.56%
6SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
2.50%
7IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
2.45%
8ASAN
ASANA INCTechnology$1.77B
2.44%
9TDOC
TELADOC HEALTH INCHealthcare$1.70B
2.34%
10VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
2.19%
11NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
2.19%
12MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
1.99%
13YELP
YELP INCCommunication Services$1.44B
1.98%
14FMC
FMC CORPBasic Materials$1.40B
1.93%
15WLTH
WEALTHFRONT CORPTechnology$1.38B
1.90%
16AI
C3AI INCTechnology$1.37B
1.89%
17NVAX
NOVAVAX INCHealthcare$1.35B
1.86%
18XNCR
XENCOR INCHealthcare$1.30B
1.78%
19TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
1.61%
20CRTO
CRITEO SACommunication Services$1.13B
1.55%
21WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
1.54%
22UPWK
UPWORK INCIndustrials$1.12B
1.54%
23EYPT
EYEPOINT INCHealthcare$1.12B
1.54%
24CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
1.50%
25OLMA
OLEMA PHARMACEUTICALS INCHealthcare$1.00B
1.38%
26VOR
VOR BIOPHARMA INCHealthcare$980M
1.35%
27KURA
KURA ONCOLOGY INCHealthcare$964M
1.33%
28ANNX
ANNEXON INCHealthcare$950M
1.31%
29ADTN
ADTRAN HOLDINGS INCTechnology$944M
1.30%
30REPL
REPLIMUNE GROUP INCHealthcare$859M
1.18%
31SLDB
SOLID BIOSCIENCES INCHealthcare$859M
1.18%
32TDUP
THREDUP INCConsumer Cyclical$852M
1.17%
33RPD
RAPID7 INCTechnology$815M
1.12%
34PD
PAGERDUTY INCTechnology$794M
1.09%
35BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INCHealthcare$686M
0.94%
36CARS
CARSCOM INCConsumer Cyclical$670M
0.92%
37PHR
PHREESIA INCHealthcare$662M
0.91%
38MYGN
MYRIAD GENETICS INCHealthcare$584M
0.80%
39FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.79%
40YEXT
YEXT INCTechnology$535M
0.74%
41VSTM
VERASTEM INCHealthcare$530M
0.73%
42SPT
SPROUT SOCIAL INCTechnology$518M
0.71%
43ARVN
ARVINAS INCHealthcare$517M
0.71%
44DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.71%
45RGNX
REGENXBIO INCHealthcare$511M
0.70%
46PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.62%
47KYTX
KYVERNA THERAPEUTICS INCHealthcare$453M
0.62%
48VREX
VAREX IMAGING CORPHealthcare$444M
0.61%
49PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.60%
50ASMB
ASSEMBLY BIOSCIENCES INCHealthcare$426M
0.59%
51CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.56%
52ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.55%
53STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.54%
54CRNC
CERENCE INCTechnology$390M
0.54%
55UPB
UPSTREAM BIO INCHealthcare$382M
0.53%
56BBBY
BED BATH & BEYOND INCConsumer Cyclical$372M
0.51%
57ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.50%
58XPER
XPERI INCTechnology$352M
0.49%
59VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.45%
60LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.43%
61FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.42%
62SSTK
SHUTTERSTOCK INCCommunication Services$272M
0.37%
63TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.37%
64ANGI
ANGI INCCommunication Services$248M
0.34%
65RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.33%
66ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.33%
67RXST
RXSIGHT INCHealthcare$230M
0.32%
68UP
WHEELS UP EXPERIENCE INCIndustrials$229M
0.32%
69SPOK
SPOK HOLDINGS INCHealthcare$222M
0.31%
70KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.30%
71SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.29%
72KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.29%
73AGEN
AGENUS INCHealthcare$209M
0.29%
74IMUX
IMMUNIC INCHealthcare$207M
0.28%
75DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.28%
76AMWL
AMERICAN WELL CORPHealthcare$199M
0.27%
77TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.27%
78SRI
STONERIDGE INCConsumer Cyclical$197M
0.27%
79EGAN
EGAIN CORPTechnology$180M
0.25%
80KRRO
KORRO BIO INCHealthcare$177M
0.24%
81ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.24%
82CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.23%
83EXOD
EXODUS MOVEMENT INCTechnology$152M
0.21%
84CHPT
CHARGEPOINT HOLDINGS INCConsumer Cyclical$146M
0.20%
85PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.19%
86FIRY
FIRY INCTechnology$130M
0.18%
87VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.18%
88AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.18%
89CUE
CUE BIOPHARMA INCHealthcare$126M
0.17%
90INSG
INSEEGO CORPTechnology$122M
0.17%
91TCX
TUCOWS INCTechnology$114M
0.16%
92SCOR
COMSCORE INCCommunication Services$113M
0.16%
93GEOS
GEOSPACE TECHNOLOGIES CORPEnergy$88M
0.12%
94RLYB
RALLYBIO CORPHealthcare$87M
0.12%
95ACET
ADICET BIO INCHealthcare$76M
0.10%
96CLNN
CLENE INCHealthcare$76M
0.10%
97BODI
BEACHBODY COMPANY INCCommunication Services$75M
0.10%
98SCLX
SCILEX HOLDING COHealthcare$72M
0.10%
99LONA
LEONABIO INCHealthcare$68M
0.09%
100IMA
IMAGENEBIO INCHealthcare$61M
0.08%
101SKIL
SKILLSOFT CORPConsumer Defensive$58M
0.08%
102LNZA
LANZATECH GLOBAL INCIndustrials$56M
0.08%
103STEM
STEM INCTechnology$56M
0.08%
104XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.07%
105MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.07%
106TIL
INSTIL BIO INCHealthcare$50M
0.07%

Full long-leg book as of July 2026 · cap-weighted · total market cap $72.64B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

8 sectors
Healthcare
60.4%
Consumer Cyclical
17.7%
Technology
13.3%
Communication Services
4.5%
Industrials
1.9%
Basic Materials
1.9%
Energy
0.1%
Consumer Defensive
0.1%

Portfolio Style

Size × value map of the long-leg book

106 classified
Value
Blend
Growth
Large
Mid
Small
·
11%1
·
8%5
24%13
12%6
13%40
7%15
4%6

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 41% toward Large, 47% toward Growth. +20% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt41% → Large
SmallLarge
Value ↔ growth tilt47% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 106 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
2
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    49.7%
    Margin
    -24.7%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    12.3 days
    Margin
    -5.3 days
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 106 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.8 (95% CI 1.3-2.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
17.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.78x
within
parametric
1.91x
within
cornish fisher
1.67x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2001
Before publication (pre-2001)
1.34
Sharpe · 44.0% p.a.
January 1999December 2001 · 36 mo
Since publication
0.35
Sharpe · 8.5% p.a.
January 2002July 2026 · 295 mo
Change in Sharpe−0.99Sharpe weakened since publication81% of the prior annual return given up

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
69%
18 of 26 3-year windows made money
Worst window
-1.02
Sharpe, January 2006 – December 2008
January 1999July 2026
Median Sharpe
0.55
Dispersion
0.75
Best window
2.20

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.129.5%112.2%
3 yearsp.a.40.1%12.0%
5 yearsp.a.25.6%4.4%
10 yearsp.a.29.2%13.9%
Since inceptionp.a.17.5%9.5%
Calendar years
YearLong legLong-short
20267 mo44.7%43.3%
202559.7%27.2%
20247.9%-32.9%
202364.9%44.5%
2022-25.8%-15.1%
202120.3%-5.3%
202035.2%2.1%
201958.0%45.3%
2018-7.9%7.9%
201752.2%41.5%
201641.1%21.2%
2015-6.7%13.1%
201429.8%39.5%
201347.1%28.5%
20127.7%-4.1%
2011-1.5%-10.2%
201028.2%1.3%
200985.4%67.4%
2008-58.9%-38.9%
2007-18.9%-40.0%
200630.7%7.0%
20055.5%-2.5%
200410.2%-11.0%
2003116.1%61.6%
2002-50.1%-39.2%
200118.8%75.3%
20007.8%84.3%
199977.1%-2.3%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FRDX
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.29% (placeholder)
Inception2019-12-15 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$72.64B

Methodology

The Foundry RD Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a RD signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.